At 1:45 ET this afternoon, Gilead Sciences will present the following abstract for GS-5734 at ICAAC in San Diego:
"Once-Daily Treatment With GS-5734 Initiated Three Days Post Viral Challenge Protects Rhesus Monkeys against Lethal Ebola Virus Disease (EVD)."
When I first posted news of this Abstract in a previous message, no additional details were available. ICAAC has now unveiled the results and conclusions of the study on the conference's website. This is what was concluded:
"GS-5734 is the first small molecule antiviral demonstrating robust therapeutic effect in monkey model of EVD. IV dosing initiated 3 days post infection was associated with 100% survival and marked suppression of EVD, supporting development of the compound as a potential treatment of EBOV infection in humans."
I seem to recall awhile back, that Tekmira was tossed about here as one of the companies that "Gilead should buy" to boost the price of their stock...